Mayfield Heights, OHNCT07855276Now EnrollingIRB Ready

Hidradenitis Suppurativa Clinical Trial in Mayfield Heights, OH

Access cutting-edge hidradenitis suppurativa treatment through this phase 1 clinical trial at a research site in Mayfield Heights. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Mayfield Heights location

Preparing your pre-screening questions…

Expert Care in Mayfield Heights

Access hidradenitis suppurativa specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hidradenitis suppurativa treatment provided free

Apply for This Mayfield Heights Location

Check if you qualify for this hidradenitis suppurativa clinical trial in Mayfield Heights, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Mayfield Heights

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Mayfield Heights site if eligible
  4. 4Begin participation

About This Hidradenitis Suppurativa Study in Mayfield Heights

This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Male and female participants ≥ 18 years to 65 years of age at the time of signing of the informed consent forms (ICF).
Diagnosis of HS based on clinical history and physical examination for at least 6 months prior to Day 1.
Participants with moderate to severe HS at Day 1 defined as:
A total of at least 5 abscesses and inflammatory nodules (AN), i.e. abscesses and/or inflammatory nodules
Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae).
At least 1 chronic lesion, which is defined by the presence of a draining tunnel and further meeting biopsy criteria as defined in the laboratory manual. Key

Exclusion Criteria

Presence of more than 20 fistulae/tunnels (both draining and non-draining) in total at baseline.
Use of other investigational drugs within 5 half-lives, or within 30 days (for small molecules) prior to randomization, or until the pharmacodynamic effect has returned to baseline (for biologics), whichever is longer.
Previous exposure to remibrutinib or other BTK inhibitors.
Previous exposure to investigational Janus Kinase (JAK) inhibitors.
Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include and are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the investigator, an HIV test can be performed to confirm eligibility.
Significant bleeding risk or coagulation disorders.
History or current hepatic disease (moderate to severe Hepatic Impairment (HI) as per Child-Pugh classification), including but not limited to, acute or chronic hepatitis (with the exception of Hepatitis B or C - see respective exclusion criterion above), cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at Screening.
Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., hormonal profile confirming menopause and/or age-appropriate history of vasomotor symptoms). WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 7 days after stopping study treatment. Highly effective contraception methods. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Mayfield Heights?

Yes, this clinical trial (NCT07855276) has an active research site in Mayfield Heights, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hidradenitis Suppurativa Treatment Options in Mayfield Heights, OH

If you're searching for hidradenitis suppurativa treatment options in Mayfield Heights, OH, this clinical trial (NCT07855276) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Mayfield Heights research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced hidradenitis suppurativa specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hidradenitis suppurativa clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Mayfield Heights, OH

See all alzheimers disease clinical trials recruiting in Mayfield Heights — not just this study.

Browse Alzheimers Disease Trials in Mayfield Heights →

Browse More Trials by Condition

Alzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsHidradenitis Suppurativa TrialsAll Conditions →

Ready to Join in Mayfield Heights?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Mayfield Heights, OH